Massoud Amanlou, Zahra Heidari, Seyed Davar Siadat, Mohammad Reza Aghasadeghi, Masoud Ghorbani, Seyed Esmaeil Sadat Ebrahimi, Seyed Mehdi Sadat, Mehdi Hajmohammadi, Ali Jabbari Arabzadeh, Soheila Hekmat, Mahmood Alaei-Beirami, Alireza Azizi Saraji, Hadi Fathi Moghaddam, Mohammad Shafiee Alavidjeh, Seyed Ali Delbaz, Abolfazl Dashtbani-Roozbehani and Mehdi Shafiee Ardestani Pages 526 - 538 ( 13 )
Tumor and especially breast cancer is among the most common causes of death worldwide. Finding novel nanosized therapeutic compounds have important role to decrease the chance of death and increase the survival. Cancer cells are highly attractive to glucose [with a nanosize bimolecular structure 1nm] as an energy source more than normal cell and nanosized therapeutics due to possessing different pharmacokinetic and pharmacodynamic have advantageous over classical dosage forms in cancer therapy. The aim of the study was to synthesize Glucosamin-Porphyrin-Tamoxifen [TPG] nanosized complex as a novel selective biocompatible anti breast cancer agent. After the synthesis procedure, this complex was purified and then tested In Vitro on breast cancer cells [MCF-7] in the absence or presence of the red light and found totally successful. The results showed a good anti breast cancer activity mediated by the activation of TNF-α and necrosis/apoptosis pathways for the nanosized complex with no alteration effects on blood PT/APTT and glucose or hexokinase levels/ activity. TPG nanoconjugate seems to be very good opponents to current anti breast cancer drugs and needs to be further investigated in near future.
Breast cancer, tamoxifen, porphyrin, glucosamine, N-demethylation, human mammary cancer cell line [MCF- 7]
Department of Hepatitis and AIDS, Pasteur Institute of Iran and Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.